Clinical Trial Update: Regorafenib in Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal Adenocarcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating regorafenib in patients with newly diagnosed metastatic colorectal adenocarcinoma and good performance status has completed,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Adenocarcinoma

Drugs mentioned

• Stivarga (regorafenib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Metastatic Colorectal Adenocarcinoma | Phase 2 | Status: COMPLETED